Van Lanschot Kempen Logo
  • Home
  • Solutions
  • News & knowledge
  • About us


Nanobiotix is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer

  • Nanobiotix completed a sub-10% private placement by issuing new shares  to US and EU institutional investors
  • Proceeds will be used for the development of lead product NBTXR3 and preparation of its market access and launch
  • Order book was of mainly long-only demand was covered by  a majority of new institutional investors and institutional investors from the US

Fully focused on your future

Private Banking

  • Offices
  • Business professionals
  • Executives
  • Doctors
  • Entrepreneurs
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions

Investment Management

Investment Banking

© Van Lanschot Kempen 2023
Privacy & cookies